ACG

ACG 2024: Anti-TNF vs. JAK inhibitor therapy for IBD: Does risk of adverse CV events differ?

November 6, 2024

Janus kinase inhibitors (JAKi) used to treat inflammatory bowel disease (IBD) are not associated with an increased risk of major adverse cardiovascular events (MACE) or venous thromboembolism (VTE) compared with anti-TNF therapy, according to a retrospective cohort study presented at the American College of Gastroenterology meeting.

Researchers analyzed data from 7,480 patients with IBD (mean age, 43 years) treated with either JAKi or anti-TNF therapy. Co-primary outcomes were MACE and VTE within 1-year after medication initiation.

Key findings: After excluding patients with a history of prior CV events, MACE events were reported in 1.76% of the JAKi cohort vs. 1.94% of the anti-TNF cohort. There was no difference between cohorts in the development of MACE (adjusted hazard ratio [aHR], 0.99; 95% CI, 0.69 - 1.42) or VTE (aHR, 0.9; 95% CI, 0.61 - 1.32). Although the MACE rate was slightly higher in the anti-TNF group in patients ≥65 years, the difference wasn’t statistically significant. Patients treated with JAKi were more likely to undergo intestinal resection surgery (aHR, 1.32), but corticosteroid use was similar across both cohorts.

Source:

Alsakarneh, S. (2024, October 30). Major Adverse Cardiovascular Events in Patients With IBD Taking Anti-TNF vs JAK Inhibitors: A Propensity Matched Cohort Analysis. Presented at the American College of Gastroenterology Annual Scientific Meeting. https://acg2024.eventscribe.net/fsPopup.asp?PresentationID=1498119&mode=presInfo